CClinicalTrials.gg
Sign In
CompletedNCT01655316Updated Nov 14, 2012

Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

A Phase 4 interventional study of Verapamil in Paroxysmal Supraventricular Tachycardia, sponsored by Tehran University of Medical Sciences. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-14.

Sponsored by Tehran University of Medical Sciences · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases.

Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent.

Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising.

This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

02

Conditions studied

  • Paroxysmal Supraventricular Tachycardia
03

In context

Tachycardia

623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.

This study's enrollment of 90 is above the median of 64 across 379 interventional studies indexed under Tachycardia.

Browse Tachycardia studies →

Lead sponsor

Tehran University of Medical Sciences is the lead sponsor of 227 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age>18 years old
  • PSVT on emergency department presentation

Exclusion criteria

Exclusion Criteria:

  • Instability in hemodynamic status
  • Allergy to Verapamil
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
Single (Participant)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Verapamil

    40 mg Verapamil Per Oral

    Drug: Verapamil

Interventions

  • DrugVerapamil
06

What researchers measure

Primary outcomes

  1. Recurrence Control

    Time frame: 2 hours

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01655316
Lead sponsor
Tehran University of Medical Sciences
Responsible party
Sponsor
First posted
Aug 1, 2012
Start date
Oct 2010
Primary completion
Aug 2011
Completion
Aug 2011
Last update
Nov 14, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Tachycardia→

Other studies from this sponsor

Tehran University of Medical Sciences

Start the discussion